- October 06, 2021Source: YaleNews
Yale researchers have identified key changes in gene expression and structure within the developing human brain that make it unique among all animal species.
- October 05, 2021
The High-Risk, High-Reward Research program stimulates scientific discovery through promoting trailblazing research that otherwise might be limited due to its inherent risk.
- September 19, 2021
Dr. Sarah Yip and Dr. Sarah Lichenstein are leading one of the first studies to investigate the neurobiology of pain and analgesia at the same time as investigating sex differences.
- September 10, 2021
Orientation selectivity enhances context generalization and generative predictive coding in the hippocampusSource: Neuron
The lab of George Dragoi, MD, PhD, Associate Professor of Psychiatry and of Neuroscience, recently published a new study in Neuron that found orientation selectivity enhances context generalization and generative predictive coding in the hippocampus.
- September 10, 2021
Strittmatter succeeds Pietro De Camilli, MD, who elected not to seek a new term after six years as chair. Jessica Cardin, PhD, becomes interim vice chair, succeeding Sreeganga Chandra, PhD.
- September 08, 2021Source: The American Society for Cell Biology (ASCB)
Each year, the American Society for Cell Biology (ASCB) chooses remarkable individuals to be recognized for their various achievements in the realm of life sciences. Pietro De Camilli received the E.B. Wilson Medal, presented to distinguished researchers for their far-reaching contributions to cell biology over a lifetime in science.
- September 07, 2021
WHRY is now accepting letters of intent for studies that advance our understanding of the health of women and/or sex/gender differences that influence health.
- September 07, 2021Source: WTNH News 8
About one-third of people diagnosed with epilepsy are not able to get relief from treatments currently available. Now, researchers at Yale University School of Medicine and two other locations are beginning trials on a new and innovative treatment that uses smart technology.
- August 27, 2021Source: Verywell Health
Ketamine, the anesthetic and pain-relieving drug sometimes used for hallucinogenic effects, could revolutionize mental health care. Yet, how and why the drug relieves depression symptoms is still clouded in mystery."Like many advances in psychiatry, the clinical breakthrough occurred before we understood how it worked to alleviate depression," John H. Krystal, MD, Chair of the Yale Department of Psychiatry, told Verywell via email.